CStone Pharmaceuticals, a biopharmaceutical company, researches and develops anti-cancer therapies to address the unmet medical needs of cancer patients in Mainland China and internationally. The company offers CEJEMLY (sugemalimab), a monoclonal antibody against programmed death (PD) ligand 1 for the treatment of non-small cell lung cancer (NSCLC), gastric adenocarcinoma/gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, and relapsed or refractory natural killer/T cell lymphoma; GAVRETO (pralsetinib), a RET inhibitor to treat patients with advanced or metastatic RET-mutant medullary and RET fusion-positive thyroid cancers, as well as NSCLC and multiple tumors; and AYVAKIT (avapritinib), a KIT/PDGFRA inhibitor, has been approved by the China NMPA for the treatment of adults with unresectable or metastatic GIST harboring a PDGFRA exon 18 mutation, including PDGFRA D842V mutations. It has strategic partnerships with Pfizer, Sanofi, Hengrui, 3SBio Inc., Allist, Ewopharma, Pharmalink, SteinCares, and Gentili. CStone Pharmaceuticals was incorporated in 2015 and is headquartered in Suzhou, China.
Frequently asked questions
What sector does CStone Pharmaceuticals (CSPHF) operate in?
CStone Pharmaceuticals belongs to the Healthcare sector and operates in the Biotechnology industry.
What is CStone Pharmaceuticals (CSPHF) current stock price?
As of the latest data, CStone Pharmaceuticals stock price is $0.76, with a previous close of $0.76.
What is CStone Pharmaceuticals (CSPHF) current market capitalization?
CStone Pharmaceuticals market cap is approximately 1.20 billion.
What is CStone Pharmaceuticals (CSPHF) Earnings Per Share (EPS)?
The trailing EPS is -$0.04.
What is CStone Pharmaceuticals (CSPHF) EBITDA?
CStone Pharmaceuticals EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -210.33 million.
Does CStone Pharmaceuticals (CSPHF) pay dividends?
No. CStone Pharmaceuticals does not pay a dividend.
What is CStone Pharmaceuticals (CSPHF) beta (volatility) score?
CStone Pharmaceuticals has a beta of 0.220, indicating lower volatility than the overall market.
